New developments in mild cognitive impairment and Alzheimer's disease

Current Opinion in Neurology

Volumn 19, Issue 6, 2006, Pages 552-558

  Schott, Jonathan M ^a   Kennedy, Jonathan ^a   Fox, Nick C ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid; Mild cognitive impairment

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RIVASTIGMINE;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC TEST; DISEASE COURSE; ENZYME INHIBITION; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; MEDICAL RESEARCH; MENINGOENCEPHALITIS; NEUROFILAMENT; NEUROIMAGING; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENILE PLAQUE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DIAGNOSTIC IMAGING; HUMANS; IMMUNOTHERAPY; PREDICTIVE VALUE OF TESTS;

EID: 33751023871     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000247611.44106.76     Document Type: Review

References (57)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366:2112-2117. This detailed systematic review of international published studies provides the most up-to-date estimate of the current worldwide prevalence of dementia and forecasts the likely future disease burden.
2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
3. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379-2388. This double-blinded prospective 3-year study showed no long-term reduction in the conversion of MCI to Alzheimer's disease following treatment either with donepezil or vitamin E.
4. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005; 62:1160-1163.
5. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63:665-672. Post-mortem results from a cohort of patients dying whilst still fulfilling diagnostic criteria for MCI revealed neuropathological changes intermediate to those seen in normal ageing and early Alzheimer's disease.
6. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63:674-681.
7. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006; 367:1262-1270. This is a review of current concepts of diagnosis and management of MCI arising from a 2005 Expert Conference.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
9. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38:24-26. Duplication of the APP locus leads to autosomal dominant early onset Alzheimer's disease with cerebral amyloid angiopathy.
10. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
11. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006; 27:570-575. A review of current evidence that amyloid oligomers share the ability to permeabilize cellular membranes and lipid bilayers.
12. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8:79-84. The demonstration that amyloid oligomers can cause rapid-onset, transient cognitive dysfunction in experimental animals in the absence of neurodegeneration, suggesting that subtle brain dysfunction and neuronal cell loss as seen in presymptomatic Alzheimer's disease might be reversible by prevention of amyloid oligomerization.
13. Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006; 281:1599-1604. Using a triple transgenic mouse expressing amyloid and tau, the authors show that oligomerization of Aβ appears to start within neurons and that the administration of oligomeric antibodies is sufficient to clear both Aβ and tau pathology.
14. Lord A, Kalimo H, Eckman C, et al. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 2006; 27:67-77.
15. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352-357. Extracellular accumulation of a soluble Aβ oligomer (Aβ*56) leads to memory deficits in transgenic APP mice. Furthermore, passive transfer of Aβ*56 is sufficient to disrupt memory transiently in young rats in the absence of plaques and tangles.
16. Lashuel HA, Hartley DM, Petre BM, et al. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003; 332:795-808.
17. Shah S, Lee SF, Tabuchi K, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005; 122:435-447.
18. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006; 96:732-742. Using wild type presenilin-deficient cells, different presenilin mutations were shown to lead to a variety of alterations in gamma-secretase structure or function and the production of amyloidogenic fragments.
19. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4:887-893.
20. Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 1998; 95:13103-13107.
21. SantaCruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309:476-481. Transgenic mice overexpressing human tau under the control of a promotor produce hyperphosphorylated tau, neurodegeneration and cognitive impairment. The authors show that supressing tau production leads to halting of neurodegeneration, improvements in memory but continued production of neurofibrillary tangles, suggesting that tangle formation alone is not sufficient to explain cell loss and memory impairment.
22. Hoshi M, Sato M, Matsumoto S, et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 2003; 100:6370-6375.
23. Guo JP, Arai T, Miklossy J, et al. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A 2006; 103:1953-1958. This paper reports that soluble Aβ binds to soluble nonphosphorylated tau and the complex thus formed leads to tau phosphorylation. Blockade of amyloid/tau binding sites might therefore prevent plaque and tangle formation.
24. Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1:13-21.
25. Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 2003; 53:181-188.
26. Rusinek H, de Santi S, Frid D, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003; 229:691-696.
27. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65:1227-1231.
28. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in Alzheimer's disease. Neurology 2004; 62:591-600.
29. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for Alzheimer's disease. Neurology 2003; 60:253-260.
30. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319.
31. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using positron emission tomography imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25:1528-1547.
32. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; Jul 19 [Epub ahead of print]. Patients with established Alzheimer's disease showed stable levels of PIB uptake over a 2-year period.
33. Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005; 8:527-533. Amyloid may be detectable using MRI.
34. Schoonenboom NS, Pijnenburg YA, Mulder C, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62:1580-1584.
35. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228-234. Combined measures of CSF tau and amyloid predict conversion from MCI to Alzheimer's disease with a sensitivity of approximately 95% and specificity of approximately 85%.
36. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59:512-519. This work demonstrates an inverse relationship between positron emission tomography measures of amyloid burden using PIB and CSF Aβ42 levels, presumed to reflect the reduction of soluble Aβ42 available for transport from brain to CSF, consequent to deposition of amyloid within plaques.
37. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An (11)C-PIB positron emission tomography study. Ann Neurol 2006; 60:145-147.
38. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1):CD005593.
39. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363:2105-2115.
40. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2):CD003154.
41. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63:49-54.
42. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324.
43. Asai M, Hattori C, Iwata N, et al. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96:533-540.
44. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66:602-604. This early study in man showed that administration of a γ-secretase inhibitor is well tolerated in Alzheimer's disease patients, and leads to significant reduction in plasma but not CSF Aβ.
45. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-177.
46. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1:24.
47. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54.
48. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448-452.
49. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-1562. Despite early termination of the AN1792 study, this paper provides some evidence to suggest that in the group as a whole, active Aβ immunization was associated with some benefits in a composite cognitive score.
50. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-554.
51. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64:1563-1572. This paper presents the surprising demonstration that despite improving cognitively, antibody responders in the AN1792 vaccination study had increased brain volume loss compared to nonresponders. Whilst the reasons underlying this finding are not clear, the authors discuss the possibility that volume changes were related to amyloid removal.
52. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64:94-101.
53. Lee M, Bard F, Johnson-Wood K, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005; 58:430-435.
54. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 2003; 100:2023-2028.
55. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8: 1263-1269.
56. Maier M, Seabrook TJ, Lazo ND, et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006; 26:4717-4728. Mice vaccinated intranasally with immune peptides targeted against Aβ 1-15 showed reduced Aβ plaque density and improved performance on a water-maze test.
57. Qu B, Boyer PJ, Johnston SA, et al. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 2006; 244:151-158. Aβ42 gene vaccine administered transdermally reduces Aβ42 burden in transgenic mice.